Biotechnology

The NHS rollout of Tryngolza offers a monthly RNA-targeted lifeline for FCS patients, proving the practical value of execution in genetic lipid disorders.

As a critical FDA decision looms for its lead drug, Hansa Biopharma partners with Cradle to build a sustainable, AI-driven autoimmune discovery engine.

Rakovina Therapeutics is teaming up with Celvion to leverage real-world AI data, aiming to bypass clinical hurdles and de-risk its ATR inhibitor pipeline.

By appointing Dr. Rajesh Chopra as CSO, Swiss biotech Numab Therapeutics signals a strategic pivot toward clinical execution for its trispecific IBD pipeline.

Pliant Therapeutics taps veteran oncologist Dr. David Raben as CMO to steer its targeted ICI-refractory cancer program toward crucial 2027 clinical milestones.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.

Quorum Innovations has published early human data on Qi601, a postbiotic designed to trap microplastics in the gut before they enter human cells.

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

As prostate cancer rates climb, top oncologists and investors converge to discuss how AI, immunotherapy, and strategic capital are redefining treatment.

NuCana's new European patent for its cancer drug NUC-7738 strengthens its global IP moat, backing its clinical push against PD-1 resistant melanoma into 2029.

French biotech EVerZom successfully completes preclinical studies for its exosome-based EVerGel, targeting a 2027 clinical debut for Crohn's disease fistulas.

Latvia's recent US trade mission secured strategic partnerships with defense and biotech giants, positioning the Baltic nation as a high-tech proving ground.

As Compass Pathways targets a 2027 launch for its psilocybin therapy, a new HR chief highlights the shift from clinical pioneer to commercial enterprise.

A new partnership between the TECPR2 Research Foundation and CDMO Forge Biologics highlights a shift: families are now acting as sophisticated biotech operators.

Invivyd's VYD2311 beats mRNA vaccines on tolerability and boosts immunity, but regulatory and economic hurdles loom large for the novel therapy.

Following its formation via private equity, Minaris reorganizes to tackle the viral vector capacity crunch and navigate the post-BIOSECURE Act landscape.

By trading toxic payloads for precise degradation, Nurix Therapeutics is writing a masterclass in biotech survival and post-merger pharmaceutical strategy.

A multi-agency GCP inspection forces AB Science to delay its lead ALS and AML trials to 2027, testing investor patience and a new turnaround strategy.

A massive €40 million seed round for an Italian biotech signals a paradigm shift in treating intractable genetic disorders like Fragile X Syndrome.

A new strategic partnership between Evosep and Mass Dynamics aims to solve proteomics’ biggest bottleneck: pre-analytical variability in drug discovery.